Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
University of Arkansas
Study ID
NCT00287222
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary efficacy endpoint will be the proportion of subjects that remain free of progression at the 27th week following the onset of treatment. Secondary objectives include the subject's time in weeks from treatment onset to documented disease progression as assessed by the RECIST criteria, response rate, median and overall survival, safety and tolerability.

Key Dates

First listed
Feb 6, 2006
Start date
Feb 28, 2006
Status verified
Jun 2011
Primary completion
Sep 30, 2010
Completion
Sep 30, 2010

Study Design

Enrollment
21 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1 - Bevacizumab/Erlotinib
    Subjects will be treated with bevacizumab and erlotinib

Primary Outcome Measure

Number of Participants Who Remained Free of Progression at the 27th Week. [ Time Frame: 27 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of Arkansas for Medical SciencesLittle RockArkansas72205-
Kansas University Medical CenterKansas CityKansas66160-

Find similar trials in Little Rock, AR

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
University of Arkansas for Medical Sciences· Little Rock, ARKansas University Medical Center· Kansas City, KS

Related Studies